Start free

Tango Therapeutics, Inc. (TNGX) insider trading

Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Nov 19, 2026.

Filings shown
18
Open-market buys
0
Open-market sells
20

Counts cover the 18 most recent Form 4 filings Tradune holds for TNGX (filed May 1 – Nov 19, 2026); the score below covers only the trailing 90 days (0 buys, 12 sells). SEC EDGAR Form 4 filings for TNGX last checked Nov 22, 2026, 09:00 UTC; the latest TNGX filing Tradune holds was filed Nov 19, 2026. This is not guaranteed to be the complete record — see TNGX's full Form 4 filing history on SEC EDGAR.

Open-market activity, last 90 days

Purchases (Form 4 code P) and sales (code S) on the 7 filings Tradune holds for TNGX filed Sep 3 – Nov 19, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.

12 open-market sales by Rule 10b5-1 checkbox

On filings with the 10b5-1 box checked
12 sales· 82,564 sh
checkbox disclosed
On filings with the box not checked
0 sales· 0 sh
not proof that no plan exists
Not comparable
0 sales· 0 sh
filed before Apr 1, 2023, or no checkbox value in the filing data

Counts are Form 4 lines as filed. The checkbox is one per filing, so every sale on a filing with the box checked is counted there even if only some of its transactions were under a plan; it records what the filer disclosed, and the three categories are not a judgement about why a sale was made.

Open-market purchases and sales by insider
Insider Buys Sells Shares bought Shares sold Value
Adam CrystalPresident, R&D 0 6 — 64,000 −$1,501,813
Jessica NewcombPrincipal Accounting Officer 0 5 — 15,231 −$356,273
John B. KetchumDirector 0 1 — 3,333 −$80,259

Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.

Insider-activity score

0/ 100

Net insider sales
0 distinct buyers0 buy · 12 sell tx

Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →

Get alerted when insiders buy the stocks you own

Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.

Free for everyone right now · no card · nothing to buy

Start free

How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).

Insider Buying at TNGX

No open-market insider purchases (Form 4 code P) were reported for TNGX between May 1, 2026 and Nov 19, 2026. The filings below may include other transaction types — sales, grants, option exercises, and tax withholding — shown for completeness; they are not open-market purchases.

Recent Form 4 filings

Source: SEC EDGAR Form 4 · transaction codes explained

John B. Ketchum Director · filed Nov 19, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 3,333 $24.08 21,604 −13% Nov 17, 2026

† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.

“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.

Adam Crystal President, R&D · filed Nov 13, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 5,000 $2.91 120,743 +4.3% Nov 11, 2026
Open-market sale 10b5-1 box checked 5,000 $25.00 115,743 −4.1% Nov 11, 2026
Option exercise Stock Option (Right to Buy) 5,000 — — — Nov 11, 2026
Adam Crystal President, R&D · filed Nov 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 1,100 $22.99 115,743 −0.9% Nov 2, 2026
Option exercise 5,000 $2.91 120,743 +4.3% Nov 2, 2026
Option exercise Stock Option (Right to Buy) 5,000 — — — Nov 2, 2026
Open-market sale 10b5-1 box checked 3,900 $22.26 116,843 −3.2% Nov 2, 2026
Jessica Newcomb Principal Accounting Officer · filed Nov 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 5,571 $22.28 53,550 −9.4% Nov 2, 2026
Open-market sale 10b5-1 box checked 1,460 $22.98 52,090 −2.7% Nov 2, 2026
Adam Crystal President, R&D · filed Oct 5, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 27,000 $5.20 142,743 +23% Oct 1, 2026
Option exercise Stock Option (Right to Buy) 27,000 — — — Oct 1, 2026
Open-market sale 10b5-1 box checked 600 $25.32 115,743 −0.5% Oct 1, 2026
Open-market sale 10b5-1 box checked 26,400 $24.45 116,343 −18% Oct 1, 2026
Jessica Newcomb Principal Accounting Officer · filed Sep 24, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 700 $22.80 66,621 −1.0% Sep 22, 2026
Open-market sale 10b5-1 box checked 5,100 $23.97 61,521 −7.7% Sep 22, 2026
Open-market sale 10b5-1 box checked 2,400 $25.17 59,121 −3.9% Sep 22, 2026
Adam Crystal President, R&D · filed Sep 3, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 27,000 $5.20 142,743 +23% Sep 1, 2026
Option exercise Stock Option (Right to Buy) 27,000 — — — Sep 1, 2026
Open-market sale 10b5-1 box checked 27,000 $22.37 115,743 −19% Sep 1, 2026
Adam Crystal President, R&D · filed Aug 5, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 5,267 $26.79 137,476 −3.7% Aug 3, 2026
Open-market sale 10b5-1 box checked 21,733 $27.35 115,743 −16% Aug 3, 2026
Option exercise 27,000 $5.20 142,743 +23% Aug 3, 2026
Option exercise Stock Option (Right to Buy) 27,000 — — — Aug 3, 2026
Adam Crystal President, R&D · filed Jul 2, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 7,371 $30.25 115,743 −6.0% Jul 1, 2026
Option exercise 27,000 $5.20 142,743 +23% Jul 1, 2026
Open-market sale 10b5-1 box checked 19,629 $29.34 123,114 −14% Jul 1, 2026
Option exercise Stock Option (Right to Buy) 27,000 — — — Jul 1, 2026
Robert Azelby Director · filed Jun 23, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 5,740 — 5,740 — Jun 19, 2026
Grant / award Stock Option (Right to Buy) 35,910 — — — Jun 19, 2026
John B. Ketchum Director · filed Jun 8, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 4,000 — 24,937 +19% Jun 5, 2026
Grant / award Stock Option (Right to Buy) 25,000 — — — Jun 5, 2026
Lesley Ann Calhoun Director · filed Jun 8, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 4,000 — 16,500 +32% Jun 5, 2026
Grant / award Stock Option (Right to Buy) 25,000 — — — Jun 5, 2026
Mace Rothenberg Director · filed Jun 8, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 4,000 — 41,500 +11% Jun 5, 2026
Grant / award Stock Option (Right to Buy) 25,000 — — — Jun 5, 2026
Sung Lee Director · filed Jun 8, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 570 — 22,870 +2.6% Jun 5, 2026
Grant / award Stock Option (Right to Buy) 3,570 — — — Jun 5, 2026
Adam Crystal President, R&D · filed Jun 3, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Stock Option (Right to Buy) 27,000 — — — Jun 1, 2026
Open-market sale 10b5-1 box checked 20,860 $23.06 115,743 −15% Jun 1, 2026
Open-market sale 10b5-1 box checked 6,140 $22.25 136,603 −4.3% Jun 1, 2026
Option exercise 27,000 $5.20 142,743 +23% Jun 1, 2026
Adam Crystal President, R&D · filed May 5, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Stock Option (Right to Buy) 27,000 — — — May 1, 2026
Open-market sale 10b5-1 box checked 1,100 $22.00 115,743 −0.9% May 1, 2026
Open-market sale 10b5-1 box checked 25,900 $21.19 116,843 −18% May 1, 2026
Option exercise 27,000 $5.20 142,743 +23% May 1, 2026
Matthew Gall Chief Financial Officer · filed May 5, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 240,000 — — — May 1, 2026
Grant / award 40,000 — 40,000 — May 1, 2026
Sung Lee Director · filed May 1, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 5,200 — — — Apr 29, 2026
Grant / award 12,300 — 22,300 +123% Apr 29, 2026

Insider filings reported around the same time

Other companies whose most recent Form 4 was filed closest to TNGX's (Nov 19, 2026).

Frequently asked about TNGX insider activity

How many insiders bought TNGX stock in these Form 4 filings?

No open-market purchases (Form 4 code P) of TNGX shares were reported by Tango Therapeutics, Inc. insiders between May 1, 2026 and Nov 19, 2026. The 18 filings shown on this page cover other transaction types — sales, grants, option exercises, and tax withholding.

Who filed the most recent Form 4 for TNGX?

The most recent Form 4 on this page was filed by John B. Ketchum (Director) on Nov 19, 2026, reporting 1 transaction. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.

What was the largest open-market TNGX insider sale shown?

The largest open-market sale among the filings shown was 26,400 TNGX shares at $24.45 (about $645,604) by Adam Crystal (President, R&D) on Oct 1, 2026. Value is shares × the price reported on the Form 4; that Form 4 has the Rule 10b5-1 box checked.

New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.

Get insider alerts for TNGX — and your whole portfolio

Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy

This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.

Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.